Sheryl Stevenson

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.

Weigh in on this month's survey question. The poll will be open until December 16, 2022.

The groups invite those attending the annual conference to join them at their event on Monday, January 16, which is free to OWL and WIO members.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.

Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.

Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.

CEO Rob Thornhill discusses the features of the device, as well as plans for a new technology called ZEPTOLINK which combines the company’s novel ZEPTO technology with any phaco device.

Complimentary registration is open for this unique meeting designed to prepare young ophthalmologists for success in early practice.

An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.

Lisa M. Nijm, MD, JD, shares highlights from the Real World Ophthalmology 'After Dark' networking reception held at the American Academy of Ophthalmology annual meeting. The next Real World Ophthalmology meeting on November 5—which will be virtual—will cover important clinical, business, and personal growth areas for young ophthalmologists.

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Mike Lyons, PHR, MHRIR, and Megan Odell, BHA, MHHR, with Austin Retina Associates, outline how to implement the GREAT and the LEAP method for an improved employee and patient experience.

At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.

Donny W. Suh, MD, finds his love for practicing pediatric ophthalmology grows stronger with each passing year. He offers two tips to fellow physicians and his residents and fellows for managing the stressors of daily practice and for getting a good night’s sleep. He also shares his journey in a book called “Catching A Star,” with all proceeds going to a medical mission program.

Murtaza Adam, MD, a vitreoretinal specialist with Colorado Retina Associates, shares a few principles he has found helpful when engaging with industry or trying to execute on your own innovation.

This glaucoma session will offer a look at how to incorporate pearls into clinical practice.

The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.

Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

The hour-long issue teaches the viewing ophthalmologist the technique and many modifications of intrascleral haptic fixation, an innovative approach when the capsule has been damage or is absent.

After a brief hiatus during the pandemic, the Flying Eye Hospital program returns.